Orthocell (ASX:OCC) share price surges 13% on study success

Shares in the medical company are surging today.

| More on:
A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Orthocell Ltd (ASX: OCC) share price is soaring today following news of clinical study success.

At the time of writing, the Orthocell share price is trading hands at 58 cents, up 12.62%.

Orthocell is developing new medical devices and cellular therapies to help people recover from injury.

Why is the share price surging?

It appears investors are responding to positive results from a clinical trial into the use of one of Orthocell's lead products, OrthoATI.

In today's release, Orthocell said its data confirmed this product could safely reduce pain in patients suffering from rotator cuff tears. OrthoATI is more effective than steroid injections for treating this injury, according to the company.

Orthocell now plans to speed up its commercialisation plans for OrthoATI in the United States, including conducting a study in front of the Food and Drug Administration.

Orthocell told the market today it believed it could use its OrthoATI treatment to help 480,000 patients per year in the US alone. The company sees this as a US$4 to $5 billion market opportunity (AU $5.6 to $7 billion).

Management commentary

Orthocell managing director Paul Anderson welcomed the news, saying it was an important milestone. He added:

We are absolutely delighted with the study results for this challenging and debilitating condition which clearly demonstrates that OrthoATI is more effective than steroid injection for treatment of rotator cuff tendinopathy with intrasubstance tendon tear.

We are now in a very strong position to progress our US commercialisation strategy to deliver the first injectable cell therapy in orthopaedics that truly addresses the cause of degeneration and returns patients to full use of their chronically damaged tendons.

Orthocell share price snapshot

The Orthocell share price has lifted more than 38% in the past 12 months and is up 27.78% this year to date.

In contrast, the benchmark S&P/ASX 200 Index (ASX: XJO) has returned nearly 11% in the past year.

Shares in the company reached a 52-week high of 66 cents, while the low was 40.5 cents.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Researchers and doctors with futuristic 3d hologram overlay for body anatomy or dna in hospital clinic.
Healthcare Shares

Why investors are watching this ASX healthcare stock

A fresh clinical update has been released.

Read more »

A Sonic Healthcare medical researcher wearing a white coat sits at her desk in a laboratory conducting a COVID-19 test
Healthcare Shares

This biotech is up more than 20% on new deal news

Revenue will flow under this global deal just announced.

Read more »

A male doctor and a woman in scrubs in the foreground smile.
Healthcare Shares

The next 3 years could be huge for this ASX healthcare stock. Here's why

Today's update has put this ASX healthcare stock back in the spotlight as investors reassess its long-term growth potential.

Read more »

A doctor sits with a patient and uses a pen to point to certain parts of her mammogram scan
Healthcare Shares

Top broker says this ASX small-cap healthcare stock could be set to double

This company is making significant clinical and commercial progress .

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

3 quality ASX healthcare shares worth buying now

Brokers think the tide is turning for these battling medical heavyweights.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Early success in battling Crohn's Disease has sent this ASX biotech's shares soaring

The early-stage results have been described as outstanding.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

Why are 4DMedical shares in a trading halt today?

The company is looking to raise fresh capital.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

This ASX biotech's shares are up strongly on good news out of the US

The addressable market for this newly approved software is huge.

Read more »